Reovirus: viral therapy for cancer 'as nature intended'.
Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief description of what is known about reovirus biology and summarises the preclinical data related to its oncolytic ability. The completed and ongoing clinical trials involving reovirus, both as a single agent and in combination with chemotherapy and radiotherapy, will be reviewed and their results discussed. Many of these clinical studies are being conducted by centres in the UK.
Comins
C
C
Department of Oncology, Postgraduate Medical School, University of Surrey, Guildford, UK. c.comins@surrey.ac.uk
Heinemann
L
L
Harrington
K
K
Melcher
A
A
De Bono
J
J
Pandha
H
H
D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods / Q000639:trends*; D030102:Orthoreovirus, Mammalian / Q000235:genetics / Q000254:growth & development / Q000502:physiology*